TYRX CITADEL/CENTURION Clinical Studies Enroll 1000th Patient

Published: Apr 02, 2012

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--TYRX®, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiovascular implantable electronic devices (CIEDs), announced today that the 1000th patient has been enrolled into the CITADEL & CENTURION clinical studies evaluating the company’s AIGISRx Antibacterial Envelope.

Back to news